Close Menu

NEW YORK ─ Bio-Techne on Monday announced that Humana, a Medicare Advantage provider, has awarded a contract effective April 1 for coverage of its ExoDx Prostate (EPI) test for men performed at its Exosome Diagnostics laboratory.

Minneapolis, Minnesota-based Bio-Techne noted that Humana serves an estimated 20 million patients in the US.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.

CNN reports that two new studies suggest the B.1.1.7 SARS-CoV-2 variant may be more transmissible, but may not lead to more severe disease.

According to the Associated Press, a Swiss program aims to shepherd long-term science projects and diplomacy.

In PNAS this week: analysis of pathway affecting acute kidney injury, parental-specific allelic expression in horse placenta, and more.